Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
UiPath and Deloitte are expanding their partnership to integrate UiPath Test Cloud into Deloitte’s Ascend platform.
The integration brings agentic AI to quality assurance workflows, targeting more autonomous software testing for large enterprises.
This collaboration focuses on enterprise delivery, with UiPath Test Cloud embedded directly into Deloitte’s existing platform.
For investors watching NYSE:PATH, this update centers on product adoption rather than short term market moves. UiPath’s share price is currently $11.16, with the stock down 29.7% year to date and down 37.6% over 3 years and 86.2% over 5 years. Against that backdrop, deeper integration with a large consulting partner highlights how the company is trying to deepen its role in enterprise automation projects.
The focus on agentic AI for testing indicates where UiPath is aiming to compete in automation over the long run, particularly in complex corporate environments. For readers tracking the stock, this type of partnership can be useful to watch as a marker of how widely the platform is being used within large transformation programs.
Stay updated on the most important news stories for UiPath by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on UiPath.
NYSE:PATH Earnings & Revenue Growth as at May 2026
4 things going right for UiPath that this headline doesn’t cover.
Investor Checklist Quick Assessment
✅ Price vs Analyst Target: UiPath trades at US$11.16 versus a consensus target of US$13.50, about 21% below where analysts expect it to be.
✅ Simply Wall St Valuation: The stock is described as trading roughly 37.1% below an estimated fair value, pointing to a valuation gap.
✅ Recent Momentum: The 30 day return is 6.7%, so the share price has recently been moving higher.
There’s only one way to know the right time to buy, sell or hold UiPath. Head to Simply Wall St’s company report for the latest analysis of UiPath’s Fair Value.
Key Considerations
📊 The Deloitte Ascend integration brings UiPath Test Cloud into a large enterprise delivery platform, which could support product usage in quality assurance workflows.
📊 Keep an eye on how management talks about customer wins, usage metrics and AI testing adoption linked to Deloitte in future updates.
⚠️ Execution risk matters here, since deeper partnerships only translate into value if enterprises actually adopt and scale these autonomous testing solutions.
Dig Deeper
For the full picture including more risks and rewards, check out the complete UiPath analysis. Alternatively, you can check out the community page for UiPath to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PATH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com